OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
OpGen, Inc. (NASDAQ: OPGN) has announced it will release its fourth quarter and full year 2022 financial results on March 29, 2023, after U.S. market close. The management team will conduct a live conference call at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Investors can join via U.S. dial-in at 1-877-704-4453 or international dial-in at 1-201-389-0920, with a replay available until April 12, 2023. OpGen focuses on molecular diagnostics and bioinformatics for infectious diseases, leveraging its product portfolio which includes Unyvero and the Acuitas AMR Gene Panel.
- OpGen's upcoming financial results may showcase potential growth in its product offerings.
- The company's focus on molecular diagnostics positions it well in the healthcare industry.
- None.
ROCKVILLE, Md., March 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and full year 2022 financial results after the close of the U.S. financial markets on Wednesday, March 29th, 2023. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.
| Conference Call Details | ||
| U.S. Dial-in Number: | 1-877-704-4453 | |
| International Dial-in Number: | 1-201-389-0920 | |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1595064&tp_key=d21054e901 | |
| Conference ID: | 13735798 | |
| Replay Details | ||
| U.S. Dial-in Number: International Dial-in Number: Replay PIN: | 1-844-512-2921 1-412-317-6671 13735798 | |
Following the conclusion of the conference call, a replay will be available through April 12, 2023. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website under Financials & Filings.
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com
OpGen Investor & Press Contact:
Alyssa Factor
Edison Group
afactor@edisongroup.com
FAQ
What date will OpGen report its Q4 and full year 2022 financial results?
What time is the OpGen conference call scheduled for?
How can I access the OpGen financial results conference call?
Where can I find more information about OpGen's business operations?
What is OpGen's focus in the healthcare industry?
